DHS COMMUNITY PARTNERS PRIMARY CARE FORMULARY ADDITION/REVISION REQUEST

INSTRUCTIONS DATE

- REQUEST MUST BE TYPED OR HAND WRITTEN.
- FILL OUT COMPLETELY INCLUDING REQUIRED SIGNATURES.
- ATTACH SUPPORTING SCIENTIFIC REFERENCES AND EVIDENCE.
- ATTACH COMPLETED CONFLICT OF INTEREST DISCLOSURE SIGNED BY REQUESTING PHYSICIAN.

 SUBMIT VIA FAX TO DHS PHARMACY AFFAIRS OFFICE AT 213-975-9623. REQUEST WILL BE REVIEWED AT A FUTURE PRIMARY CARE PANEL COMMITTEE MEETING. 					
EVALUATION CRITERIA: NEED (RELATIVE TO THE DISEASE STATES AND CONDITIONS OF PATIENTS TREATED) EFFECTIVENESS (EFFICACY, PHARMACOKINETIC PROPERTIES, BIOEQUIVALENCE, THERAPEUTIC EQUIVALENCE) SAFETY (ADVERSE EFFECTS, MEDICATION SAFETY CONSIDERATIONS) FINANCIAL (PHARMACOECONOMIC IMPACT)					
REQUESTED DRUG	GENERIC NAME				
	BRAND NAME AND MANUFACTURER				
	DOSAGE FORMS AND STRENGTHS				
TYPE OF REQUEST (PLEASE "X")	ADDITION		RESTRICTIO	RESTRICTION CHANGE	
	NEW STRENGTH/DOSAGE FORM		DELETION	DELETION	
DESCRIPTION OF REQUEST (PLEASE "X")	A NEW PRODUCT WITH PHARMACOLOGIC EFFECTS UNLIKE OTHER FORMULARY PRODUCTS				
	AN IMPROVEMENT ON A FORMULARY PRODUCT NAME OF DRUG		OF DRUG		
	DELETE FORMULARY DRUG YES	NO EXPL	AIN BELOW		
REASON FOR REQUEST PLEASE INCLUDE PHARMACOLOGICAL EFFECTS AND PROPOSED USE. IF THIS DRUG IS SIMILAR TO A STANDARD ITEM, LIST THE ADVANTAGES OF THE STANDARD ITEM AND ADVANTAGES OF THIS DRUG					
FORMULARY RESTRICTION RECOMMENDATION					
PHYSICIAN'S PRINTED NAME		SERVICE		MAIL LOCATION	
PHYSICIAN'S SIGNATURE		TELEPHONE NUMBER		E-MAIL ADDRESS	
COMMUNITY PARTNER AGENCY CMO SIGNATURE		TITLE		ESTIMATED MONTHLY CONSUMPTION	
	ERAPEUTICS COMMITTEE USE			DATE	
APPROVEDNo		OT APPROVED			